Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04113564
Other study ID # CNS7056-016
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 3, 2015
Est. completion date November 20, 2015

Study information

Verified date October 2019
Source Paion UK Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered remimazolam to an intravenous formulation in healthy volunteers


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date November 20, 2015
Est. primary completion date November 20, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Willing to participate in the study, willing to give written informed consent prior to the initiation of any protocol-specific procedures, and willing to comply with the study restrictions.

2. Had to be able to speak, read, and understand English sufficiently to allow completion of all study assessments.

3. Gender : males and/or females

4. Age : 18 - 55 years, inclusive

5. Body mass index (BMI) : 18.0 - 32.0 kg/m2

6. Weight : =50 kg

7. Healthy status was defined by the absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, clinical chemistry, serology, and urinalysis.

8. Ability and willingness to abstain from alcohol, caffeine, and xanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to admission to the clinical facility on Day -1 until study discharge.

9. All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Investigator.

10. Females of childbearing potential and males and their female partner(s) of childbearing potential had to agree to use 2 forms of contraception, 1 of which had to be a barrier method, during the study and for 90 days after the last drug administration. Acceptable barrier forms of contraception were condom and diaphragm. Acceptable non-barrier forms of contraception for this study were an intrauterine device (IUD) and/or spermicide.

11. For females: a negative pregnancy test at Screening and Day -1.

12. Postmenopausal females: defined as 12 months with no menses prior to Screening and a serum follicle stimulating hormone (FSH) >40 IU/L at Screening.

13. All non-regular medication (including over-the-counter [OTC] medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to admission to the clinical research center. An exception was made for paracetamol (acetaminophen), which was allowed up to admission to the clinical research center.

Exclusion Criteria:

1. Women who were pregnant or lactating.

2. Males with female partners who were pregnant or lactating.

3. Use of any investigational drug or device within 30 days of the first dose of study medication.

4. Any disease which, in the opinion of the Investigator, posed an unacceptable risk to the subjects.

5. Known allergy, hypersensitivity or prior intolerance to benzodiazepine derivates or flumazenil, or a medical condition such that these agents were contraindicated.

6. The use of tobacco products within 60 days prior to the first drug administration.

7. Routine or chronic use of more than 3 grams of acetaminophen daily.

8. Strenuous activity, sunbathing and contact sports within 48 hours (2 days) prior to admission to the clinical facility and for the duration of the study.

9. History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical research center or planned donation before 30 days had elapsed since intake of study drug.

10. Plasma or platelet donation within 7 days of dosing and throughout the entire study.

11. History of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption was prohibited from 48 hours prior to admission to the clinical facility and throughout the entire study until discharge.

12. Positive screening test for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies.

13. Positive results for drugs of abuse, including cotinine, in the urine at Screening or Day -1.

14. Positive results for alcohol abuse, as determined by alcohol breath test, at Screening or Day -1.

15. Inability to be venipunctured or tolerate venous access as determined by the Investigator or designee.

16. History of clinically significant, recent/current and nonremote suicidal ideations or suicide attempts that, in the opinion of the Investigator, posed an unacceptable risk to the subject for participating in the study.

17. Any major surgery within 4 weeks of study drug administration. NOTE: Any parameter/test could be repeated at the Investigator's discretion during Screening and/or on Day -1.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Remimazolam


Locations

Country Name City State
United States PRA Health Sciences (PRA) - Early Development Services (EDS) Salt Lake City Utah

Sponsors (2)

Lead Sponsor Collaborator
Paion UK Ltd. PRA Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute oral bioavailability of remimazolam Single-dose bioavailability of an oral formulation of remimazolam relative to an IV formulation of remimazolam in healthy male and female subjects Day 1 (pre-dode) to Day 3
Secondary Maximum Plasma concentration (Cmax) Maximum observed plasma concentration Day 1 (pre-dode) to Day 3
Secondary Time to Maximum Plasma concentration (Tmax) Time to attain maximum observed plasma concentration Day 1 (pre-dode) to Day 3
Secondary Area under the plasma concentration-time curve (AUC0-t) Area under the plasma concentration-time curve from time 0 up to the time of the last measurable concentration Day 1 (pre-dode) to Day 3
Secondary Elimination half-life (T1/2) Terminal elimination half-life Day 1 (pre-dode) to Day 3
Secondary Clearance (CL/F) Apparent oral clearance Day 1 (pre-dode) to Day 3
Secondary Volume of Distribution (Vz/F) Apparent volume of distribution at terminal phase Day 1 (pre-dode) to Day 3
Secondary Incidences of Treatment-emergent adverse events Incidences of Treatment-emergent adverse events Day 1 (pre-dode) to Day 3
See also
  Status Clinical Trial Phase
Completed NCT06043739 - Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects Phase 1
Completed NCT02557139 - Bioavailability of Belumosudil (KD025) in Healthy Male Subjects Phase 1
Completed NCT02010944 - A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Not yet recruiting NCT01136551 - Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A N/A
Completed NCT04097808 - Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects N/A
Active, not recruiting NCT06098001 - Bioavailability Study of Hemp Phenolics N/A
Completed NCT01912144 - Absorption of Phenolic Acids From Coffee in Humans N/A
Completed NCT03915626 - Effect of Heat on Rivastigmine TDS Products Early Phase 1
Completed NCT01448772 - Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions Phase 1
Completed NCT01464450 - Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants Phase 1
Completed NCT01181973 - Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects Phase 1
Completed NCT00858767 - Arabic Gum-Absorption Study N/A
Completed NCT04645394 - Bioavailability of Anthocyanins From Aronia Extract in Healthy Men - a Pilot Study N/A
Completed NCT03485885 - Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects
Completed NCT05840848 - Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males N/A
Completed NCT02986529 - A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects Phase 1
Completed NCT01789359 - Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding N/A
Completed NCT01638143 - Bio-equivalence Study N/A
Completed NCT00755872 - Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate Phase 1